Treatment Patterns and Clinical Outcomes Among Patients Receiving Anlotinib in Combination With PD-1 Inhibitor for Advanced/Metastatic Esophageal Squamous Cell Carcinoma in Real-world Settings(APEC)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Programmed cell death 1 receptor antagonists (Primary)
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms APEC

07 Jun 2022 Status changed from not yet recruiting to recruiting, as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Results (n=21)of retrospectively analysis assessing the effect of anlotinib plus PD-1 inhibitor as later-line therapy on the survival of ESCC in the real world, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
04 Aug 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com